$79.00
PT-141 (Bremelanotide)
- Enhances sexual desire and libido in both men and women
- Improves sexual arousal for better physical and emotional response
- FDA-approved for treating Hypoactive Sexual Desire Disorder (HSDD)
- Works by targeting brain receptors, not cardiovascular system
- Effective for both female sexual arousal disorder (FSAD) and erectile dysfunction (ED)
- Users report increased energy and vitality beyond sexual benefits
- Enhances libido and sexual arousal
- Works in both men and women
- Acts centrally on melanocortin system (not vascular)
- API per Vial: 10 mg
- Dose: 0.25-1.75mg
- Frequency: On demand
- Route: SQ
47 in stock
Description
What is PT-141?
PT-141, also known as Bremelanotide, is a synthetic peptide that has gained attention for its potential to treat sexual dysfunction, including female sexual arousal disorder (FSAD) and erectile dysfunction (ED). PT-141 is an analog of alpha-MSH, a naturally occurring hormone that enhances libido and sexual arousal. Unlike its well-known competitor, Viagra, this peptide works by targeting the brain, not the heart. PT-141 users also report feeling healthier and more energized even outside of the bedroom.
How Does PT-141 Work?
PT-141 works by activating melanocortin receptors in the brain, specifically MC4R and MC3R. This activation leads to increased sexual desire and arousal, making it a promising option for individuals with sexual dysfunction.
The Science Behind PT-141
PT-141, scientifically known as Bremelanotide, operates by targeting and activating specific receptors in the brain called melanocortin receptors, primarily MC4R (Melanocortin 4 Receptor) and MC3R (Melanocortin 3 Receptor). These receptors are part of the melanocortin system, which plays a crucial role in regulating a wide range of physiological functions, including sexual desire and arousal. When PT-141 binds to these receptors, it triggers a cascade of neural signals that result in increased sexual desire and improved sexual response.
Primary Benefits
- Enhanced Sexual Desire: Increases sexual desire and libido in both men and women
- Improved Sexual Arousal: Makes it easier to become physically and emotionally aroused
- Treating Sexual Dysfunction: Addresses FSAD and ED effectively
- Improved Overall Vitality: Users report feeling healthier and more energized even outside of the bedroom
FDA Approval
PT-141 is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HSDD (Hypoactive Sexual Desire Disorder) in premenopausal women. It is also being studied for potential use in treating male sexual dysfunction.
Administration
PT-141 is typically administered through subcutaneous injections. The dosage and timing may vary depending on individual needs and medical guidance.
Potential Side Effects
Common side effects can include nausea, flushing, and headaches. These effects are generally mild and short-lived.
Best For
Individuals with sexual dysfunction or low libido seeking to enhance sexual desire and arousal in a safe, effective manner.
The Future of PT-141
PT-141 represents an exciting development in sexual dysfunction treatment, and ongoing research aims to further understand its mechanisms and expand its applications. Its potential to address sexual arousal and desire issues in both men and women offers hope for improved sexual health and relationships.
Overview
PT-141 (Bremelanotide)
Category: Sexual Health & Performance
How It Works
PT-141 works by activating melanocortin receptors in the brain, specifically MC4R and MC3R. This activation triggers neural signals that result in increased sexual desire and improved sexual response. Unlike Viagra, it works by targeting the brain, not the cardiovascular system.
Benefits
- Enhances libido and sexual arousal
- Works in both men and women
- Acts centrally on melanocortin system (not vascular)
- Rapid onset (~45-90 minutes, effect may last 8-12 hours)
- FDA-approved for on-demand treatment of HSDD in premenopausal women
Best For
- Individuals with sexual dysfunction or low libido, female sexual arousal disorder (FSAD), erectile dysfunction (ED), and those seeking to enhance sexual desire and arousal
Recommended Protocol
| API per Vial | 10 mg |
|---|---|
| Dosage | 0.25-1.75mg |
| Frequency | On demand |
| Administration | SQ |
| Cycle Length | As needed (intermittent) |
| Break Period | FDA limits to 8 doses/month |
| Half-Life | 2-3 hours |
Safety Information
Experience Level: Intermediate
Medical Supervision: Not Required
Contraindications
- Uncontrolled hypertension
- Significant cardiovascular disease
Recommended Monitoring
- Blood pressure monitoring|Sexual function assessment|Side effect tracking|Overall vitality and energy levels|Cardiovascular health monitoring
Regulatory Status: FDA-approved for HSDD in premenopausal women (Vyleesi)
Additional Notes
AVOID in patients with uncontrolled hypertension or significant cardiovascular disease — may transiently raise BP/lower HR. Many clinics start at 0.25-1mg to assess tolerance due to nausea.
